Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C2 | P52895 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | METAP1 | P53582 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 2/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17853891 | 0.89 | METAP1 (0.46) | METAP1NQO2MTNR1AMTNR1BKDM4E | |
| SCHEMBL6933096 | 0.87 | METAP1 (0.44) | METAP1NQO2MTNR1AMTNR1B | |
| SCHEMBL17854896 | 0.87 | METAP1 (0.44) | METAP1NQO2MTNR1AMTNR1BKDM4E | |
| SCHEMBL11665237 | 0.84 | BRD4 (0.46) | KDM4EALDH1A1POLBGAAL3MBTL1 | |
| SCHEMBL11661492 | 0.83 | SMN1; SMN2 (0.43) | HSD17B10KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL20409091 | 0.82 | HSD17B10 (0.41) | HSD17B10KDM4EALDH1A1HPGDGAA | |
| SCHEMBL11663913 | 0.82 | METAP1 (0.42) | METAP1KDM4EALDH1A1SMN1; SMN2GAA | |
| SCHEMBL9142278 | 0.81 | AKR1B1 (0.45) | ALDH1A1HPGDCYP2C9CA2 | |
| SCHEMBL8432398 | 0.79 | METAP1 (0.44) | METAP1NQO2MTNR1AMTNR1BKDM4E | |
| SCHEMBL11662750 | 0.79 | ABCB11 (0.38) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479813-B2 | Method of therapeutically treating cancer | ADT PHARMACEUTICALS, LLC (US) | 2025-11-25 | — | — | US | disclosed |
| US-11834404-B2 | Derivatives of sulindac can protect normal cells against oxidative damage | UNIVERSITY OF SOUTH ALABAMA (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230210849-A1 | CADHERIN-11 INHIBITOR FORMULATION AND ITS USES IN IMMUNOTHERAPY | GEORGETOWN UNIVERSITY (US) | 2023-07-06 | — | — | US | disclosed |
| EP-3233794-B1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS LLC (US) | 2023-02-01 | — | — | EP | disclosed |
| EP-3233794-B1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS LLC (US) | 2023-02-01 | — | — | EP | disclosed |
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, LLC (US) | 2022-10-06 | — | — | US | disclosed |
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, LLC (US) | 2022-10-06 | — | — | US | disclosed |
| EP-4053105-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT Pharmaceuticals, LLC (US) | 2022-09-07 | — | — | EP | disclosed |
| US-11407727-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | ADT PHARMACEUTICALS, LLC (US) | 2022-08-09 | — | — | US | disclosed |
| US-20220106250-A1 | DERIVATIVES OF SULINDAC CAN PROTECT NORMAL CELLS AGAINST OXIDATIVE DAMAGE | UNIVERSITY OF SOUTH ALABAMA (US) | 2022-04-07 | — | — | US | disclosed |
| EP-0723442-A4 | LACTONE COMPOUNDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS INC (US) | 1997-06-11 | — | — | EP | disclosed |
| EP-0769940-A4 | — | — | 1997-06-11 | — | — | EP | disclosed |
| EP-0769940-A1 | INDENE sPLA 2? INHIBITORS | ELI LILLY AND COMPANY (US) | 1997-05-02 | — | — | EP | disclosed |
| EP-0723442-A1 | LACTONE COMPOUNDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS, INC. (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1996003987-A1 | LACTONE COMPOUNDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS, INC. (US) | 1996-02-15 | — | — | WO | disclosed |
| WO-1996003120-A1 | INDENE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-02-08 | — | — | WO | disclosed |
| EP-0142801-B1 | INDENE DERIVATIVES USEFUL AS PAF-ANTAGONISTS | MERCK & CO. INC. (US) | 1989-05-31 | — | — | EP | disclosed |
| US-4656190-A | PLATELET ACTIVATING FACTOR | MERCK & CO., INC. (US) | 1987-04-07 | — | — | US | disclosed |
| EP-0142801-A2 | Indene derivatives useful as paf-antagonists | MERCK & CO. INC. (US) | 1985-05-29 | — | — | EP | disclosed |
| US-4087549-A | Sulphonic acid containing indenyl derivatives | MERCK & CO., INC. (US) | 1978-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | INSRR, INSR, BRCA1 | AKR1C2 1136/4885HSD17B10 2901/4885PTGS1 737/4885 |
| US-11834404-B2 | Derivatives of sulindac can protect normal cells against oxidative damage | PRDX3, PRDX5, SQOR | AKR1C2 1203/4885HSD17B10 1014/4885PTGS1 47/4885 |
| US-12479813-B2 | Method of therapeutically treating cancer | RECQL, RDX, RNASE1 | AKR1C2 1327/4885HSD17B10 3129/4885PTGS1 1281/4885 |
| US-11407727-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | INSRR, INSR, BRCA1 | AKR1C2 1136/4885HSD17B10 2901/4885PTGS1 737/4885 |
| US-20230210849-A1 | CADHERIN-11 INHIBITOR FORMULATION AND ITS USES IN IMMUNOTHERAPY | CDH1, DSC1, EPCAM | AKR1C2 3601/4885HSD17B10 4253/4885PTGS1 3040/4885 |
| US-20220106250-A1 | DERIVATIVES OF SULINDAC CAN PROTECT NORMAL CELLS AGAINST OXIDATIVE DAMAGE | PRDX3, PRDX5, SQOR | AKR1C2 1203/4885HSD17B10 1014/4885PTGS1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.